Metformin for cancer prevention: a reason for optimism

[...]the results establish the anti-neoplastic efficacy of metformin in non-diabetic patients, refuting the notion that the association of metformin with lower cancer risk recorded in patients with diabetes is merely due to improved disease control.

Saved in:
Bibliographic Details
Published in:The lancet oncology 2016-04, Vol.17 (4), p.407-409
Main Author: Chan, Andrew T
Format: Article
Language:English
Subjects:
Biomarkers
Colorectal cancer
Diabetes
Disease prevention
Hematology, Oncology and Palliative Medicine
Insulin
Insulin resistance
Kinases
Obesity
Studies
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c566t-47169c3291765d7b42f6b11b79a26728d974538fdae9c460ac5ee91beac4059e3
cites cdi_FETCH-LOGICAL-c566t-47169c3291765d7b42f6b11b79a26728d974538fdae9c460ac5ee91beac4059e3
container_end_page 409
container_issue 4
container_start_page 407
container_title The lancet oncology
container_volume 17
creator Chan, Andrew T
description [...]the results establish the anti-neoplastic efficacy of metformin in non-diabetic patients, refuting the notion that the association of metformin with lower cancer risk recorded in patients with diabetes is merely due to improved disease control.
doi_str_mv 10.1016/S1470-2045(16)00006-1
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1797541114</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1470204516000061</els_id><sourcerecordid>4010406001</sourcerecordid><originalsourceid>FETCH-LOGICAL-c566t-47169c3291765d7b42f6b11b79a26728d974538fdae9c460ac5ee91beac4059e3</originalsourceid><addsrcrecordid>eNqFkEtL7TAURoNc8XH0JyiFO9FBNbvNo3GgiPgCxYE6Dmm6C_G2zTHpEfz35pyqF5yYyc5j5Uv2ImQP6BFQEMePwCTNC8r4AYhDmobIYY1spW2Wc1ZVf1bzCdkk2zG-UAoSKN8gm4VQTJYl3SLiHsfWh94NWSqZNYPFkM0DvuEwOj-cZCYLaKKfzv18dL2L_Q5Zb00Xcfezzsjz1eXTxU1-93B9e3F-l1suxJgzCULZslAgBW9kzYpW1AC1VKYQsqgaJRkvq7YxqCwT1FiOqKBGYxnlCssZOZhy58G_LjCOOr1usevMgH4RNUglOQMAltC_P9AXvwhD-l2iZMWEpKnlGeETZYOPMWCr58H1JrxroHopVq_E6qU1nVYrsRrSvf3P9EXdY_N968tkAs4mAJOON4dBR-sw2WxcQDvqxrtfnzj9kWA7Nzhrun_4jvF_NzoWmk4hywwQqwQoPwBwQZno</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1778467073</pqid></control><display><type>article</type><title>Metformin for cancer prevention: a reason for optimism</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Chan, Andrew T</creator><creatorcontrib>Chan, Andrew T</creatorcontrib><description>[...]the results establish the anti-neoplastic efficacy of metformin in non-diabetic patients, refuting the notion that the association of metformin with lower cancer risk recorded in patients with diabetes is merely due to improved disease control.</description><identifier>ISSN: 1470-2045</identifier><identifier>EISSN: 1474-5488</identifier><identifier>DOI: 10.1016/S1470-2045(16)00006-1</identifier><identifier>PMID: 26947330</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Biomarkers ; Colorectal cancer ; Diabetes ; Disease prevention ; Hematology, Oncology and Palliative Medicine ; Insulin ; Insulin resistance ; Kinases ; Obesity ; Studies ; Tumors</subject><ispartof>The lancet oncology, 2016-04, Vol.17 (4), p.407-409</ispartof><rights>Elsevier Ltd</rights><rights>2016 Elsevier Ltd</rights><rights>Copyright Elsevier Limited Apr 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c566t-47169c3291765d7b42f6b11b79a26728d974538fdae9c460ac5ee91beac4059e3</citedby><cites>FETCH-LOGICAL-c566t-47169c3291765d7b42f6b11b79a26728d974538fdae9c460ac5ee91beac4059e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26947330$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chan, Andrew T</creatorcontrib><title>Metformin for cancer prevention: a reason for optimism</title><title>The lancet oncology</title><addtitle>Lancet Oncol</addtitle><description>[...]the results establish the anti-neoplastic efficacy of metformin in non-diabetic patients, refuting the notion that the association of metformin with lower cancer risk recorded in patients with diabetes is merely due to improved disease control.</description><subject>Biomarkers</subject><subject>Colorectal cancer</subject><subject>Diabetes</subject><subject>Disease prevention</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Insulin</subject><subject>Insulin resistance</subject><subject>Kinases</subject><subject>Obesity</subject><subject>Studies</subject><subject>Tumors</subject><issn>1470-2045</issn><issn>1474-5488</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqFkEtL7TAURoNc8XH0JyiFO9FBNbvNo3GgiPgCxYE6Dmm6C_G2zTHpEfz35pyqF5yYyc5j5Uv2ImQP6BFQEMePwCTNC8r4AYhDmobIYY1spW2Wc1ZVf1bzCdkk2zG-UAoSKN8gm4VQTJYl3SLiHsfWh94NWSqZNYPFkM0DvuEwOj-cZCYLaKKfzv18dL2L_Q5Zb00Xcfezzsjz1eXTxU1-93B9e3F-l1suxJgzCULZslAgBW9kzYpW1AC1VKYQsqgaJRkvq7YxqCwT1FiOqKBGYxnlCssZOZhy58G_LjCOOr1usevMgH4RNUglOQMAltC_P9AXvwhD-l2iZMWEpKnlGeETZYOPMWCr58H1JrxroHopVq_E6qU1nVYrsRrSvf3P9EXdY_N968tkAs4mAJOON4dBR-sw2WxcQDvqxrtfnzj9kWA7Nzhrun_4jvF_NzoWmk4hywwQqwQoPwBwQZno</recordid><startdate>20160401</startdate><enddate>20160401</enddate><creator>Chan, Andrew T</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20160401</creationdate><title>Metformin for cancer prevention: a reason for optimism</title><author>Chan, Andrew T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c566t-47169c3291765d7b42f6b11b79a26728d974538fdae9c460ac5ee91beac4059e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Biomarkers</topic><topic>Colorectal cancer</topic><topic>Diabetes</topic><topic>Disease prevention</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Insulin</topic><topic>Insulin resistance</topic><topic>Kinases</topic><topic>Obesity</topic><topic>Studies</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chan, Andrew T</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>The lancet oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chan, Andrew T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metformin for cancer prevention: a reason for optimism</atitle><jtitle>The lancet oncology</jtitle><addtitle>Lancet Oncol</addtitle><date>2016-04-01</date><risdate>2016</risdate><volume>17</volume><issue>4</issue><spage>407</spage><epage>409</epage><pages>407-409</pages><issn>1470-2045</issn><eissn>1474-5488</eissn><coden>LANCAO</coden><abstract>[...]the results establish the anti-neoplastic efficacy of metformin in non-diabetic patients, refuting the notion that the association of metformin with lower cancer risk recorded in patients with diabetes is merely due to improved disease control.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>26947330</pmid><doi>10.1016/S1470-2045(16)00006-1</doi><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1470-2045
ispartof The lancet oncology, 2016-04, Vol.17 (4), p.407-409
issn 1470-2045
1474-5488
language eng
recordid cdi_proquest_miscellaneous_1797541114
source ScienceDirect Freedom Collection 2022-2024
subjects Biomarkers
Colorectal cancer
Diabetes
Disease prevention
Hematology, Oncology and Palliative Medicine
Insulin
Insulin resistance
Kinases
Obesity
Studies
Tumors
title Metformin for cancer prevention: a reason for optimism
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T01%3A20%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metformin%20for%20cancer%20prevention:%20a%20reason%20for%20optimism&rft.jtitle=The%20lancet%20oncology&rft.au=Chan,%20Andrew%20T&rft.date=2016-04-01&rft.volume=17&rft.issue=4&rft.spage=407&rft.epage=409&rft.pages=407-409&rft.issn=1470-2045&rft.eissn=1474-5488&rft.coden=LANCAO&rft_id=info:doi/10.1016/S1470-2045(16)00006-1&rft_dat=%3Cproquest_cross%3E4010406001%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c566t-47169c3291765d7b42f6b11b79a26728d974538fdae9c460ac5ee91beac4059e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1778467073&rft_id=info:pmid/26947330&rfr_iscdi=true